+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019

  • ID: 4767146
  • Drug Pipelines
  • April 2019
  • Region: Global
  • 73 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Arcus Biosciences Inc
  • Calithera Biosciences Inc
  • I-Mab Biopharma Co Ltd
  • InteRNA Technologies BV
  • Novartis AG
  • Peloton Therapeutics Inc
  • MORE
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019

Summary

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5'-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.

Furthermore, this report also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
  • The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Arcus Biosciences Inc
  • Calithera Biosciences Inc
  • I-Mab Biopharma Co Ltd
  • InteRNA Technologies BV
  • Novartis AG
  • Peloton Therapeutics Inc
  • MORE
Introduction

Report Coverage

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development

Arcus Biosciences Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Corvus Pharmaceuticals Inc

Evotec AG

I-Mab Biopharma Co Ltd

Innate Pharma SA

InteRNA Technologies BV

MedImmune LLC

Novartis AG

Oric Pharmaceuticals Inc

Peloton Therapeutics Inc

Selvita SA

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles

AB-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-708 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-1B3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-5301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NZV-930 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-2828 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJ-4309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones

Featured News & Press Releases

Apr 02, 2019: Calithera Biosciences presents new preclinical data for CB-708 at AACR Annual Meeting 2019

Apr 01, 2019: Innate Pharma presents on its oncology drug candidate IPH-5301 at the american association of cancer research (aacr) 2019 annual meeting

Mar 25, 2019: InteRNA appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

Feb 28, 2019: Arcus Biosciences announces presentation on its oncology drug candidate AB680 at the 2019 American Association for Cancer Research Annual Meeting

Feb 27, 2019: Calithera Biosciences announces CB-708 preclinical data presentation at the AACR Annual Meeting 2019

Feb 06, 2019: Corvus presents updated clinical results from lead pipeline program CPI-006 at Immuno-Oncology 360° Conference

Jan 30, 2019: Corvus Pharmaceuticals to present updated biomarker and clinical data on lead development program CPI-006 at Immuno-Oncology 360° Conference

Jan 22, 2019: I-Mab Biopharma receives U.S. FDA IND clearance for proprietary CD73 antibody TJD5

Jan 08, 2019: Corvus announces enrollment in second arm of phase 1/1b dose-escalation trial of anti-CD73 antibody, CPI-006, focused on combination with CPI-444 Adenosine antagonist

Dec 26, 2018: TRACON Pharmaceuticals announces submission of IND application for TJ4309 (CD73 Antibody TJD5) for treatment of advanced solid tumors

Nov 10, 2018: Corvus Pharmaceuticals announces updated results from ongoing clinical studies of lead program, CPI-006, at SITC 33rd Annual Meeting

Nov 06, 2018: Corvus Pharmaceuticals to present CPI-006 at Investor & Analyst Event on November 10, 2018

Oct 25, 2018: Halozyme announces first clinical dosing in Bristol-Myers Squibb's phase 1 trial of BMS-986179 with Enhanze technology

Oct 22, 2018: Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker that can potentially identify patients most likely to benefit from therapies targeting adenosine pathway

Oct 04, 2018: Corvus Pharmaceuticals to present data on lead programme CPI-006 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Arcus Biosciences Inc, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Calithera Biosciences Inc, H1 2019

Pipeline by Corvus Pharmaceuticals Inc, H1 2019

Pipeline by Evotec AG, H1 2019

Pipeline by I-Mab Biopharma Co Ltd, H1 2019

Pipeline by Innate Pharma SA, H1 2019

Pipeline by InteRNA Technologies BV, H1 2019

Pipeline by MedImmune LLC, H1 2019

Pipeline by Novartis AG, H1 2019

Pipeline by Oric Pharmaceuticals Inc, H1 2019

Pipeline by Peloton Therapeutics Inc, H1 2019

Pipeline by Selvita SA, H1 2019

Dormant Projects, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Arcus Biosciences Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • Corvus Pharmaceuticals Inc
  • Evotec AG
  • I-Mab Biopharma Co Ltd
  • Innate Pharma SA
  • InteRNA Technologies BV
  • MedImmune LLC
  • Novartis AG
  • Oric Pharmaceuticals Inc
  • Peloton Therapeutics Inc
  • Selvita SA
Note: Product cover images may vary from those shown
Adroll
adroll